Intracoronary Tirofiban for No-Reflow in STEMI Patients

This clinical study focuses on patients experiencing a heart attack known as ST-segment-elevation myocardial infarction (STEMI). This condition often occurs when a plaque in the artery ruptures, obstructing blood flow to the heart. To restore this blood flow, a procedure called primary percutaneous coronary intervention (PCI) is typically used. However, a common issue called the "no-reflow" phenomenon can occur, leading to further complications. This study investigates whether using a drug called intracoronary tirofiban right after opening the blocked artery can help reduce the risk of no-reflow, potentially improving outcomes for patients. Participants in this study undergo the PCI procedure to address the blockage in their coronary artery. After the artery is opened, they receive the drug tirofiban directly into the coronary artery. The study aims to evaluate the effectiveness of this approach by observing if it reduces the occurrence of no-reflow. Although the study does not specify exact benefits or risks, the goal is to determine if this treatment strategy can lead to better recovery and fewer complications following a heart attack.